- Home
- Publications
- Publication Search
- Publication Details
Title
RANKL as a therapeutic target of rheumatoid arthritis
Authors
Keywords
-
Journal
JOURNAL OF BONE AND MINERAL METABOLISM
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-18
DOI
10.1007/s00774-020-01159-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial
- (2019) Kenneth G. Saag et al. Arthritis & Rheumatology
- Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
- (2019) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
- (2018) Kenneth G Saag et al. Lancet Diabetes & Endocrinology
- Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis
- (2017) Tetsuo Hasegawa et al. JOINT BONE SPINE
- Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis
- (2017) Takeshi Mochizuki et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Novel treatment strategies in rheumatoid arthritis
- (2017) Gerd R Burmester et al. LANCET
- Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis
- (2017) Georg Schett Modern Rheumatology
- RANKL: A therapeutic target for bone destruction in rheumatoid arthritis
- (2017) Sakae Tanaka et al. Modern Rheumatology
- Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis
- (2016) Hayato Kinoshita et al. Modern Rheumatology
- Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients withRheumatoId arthritis on methotrexate toValidate inhibitory effect on boneErosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation
- (2015) Lynett Danks et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis and incident fracture in women: a case–control study
- (2014) Sharon L Brennan et al. BMC MUSCULOSKELETAL DISORDERS
- Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture
- (2014) K. Ochi et al. OSTEOPOROSIS INTERNATIONAL
- Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients
- (2013) Yasunori Omata et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis
- (2013) Noriko Komatsu et al. NATURE MEDICINE
- Osteopetrosis: genetics, treatment and new insights into osteoclast function
- (2013) Cristina Sobacchi et al. Nature Reviews Endocrinology
- Management of rheumatoid arthritis: the 2012 perspective
- (2012) Hisashi Yamanaka et al. Modern Rheumatology
- Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study
- (2011) Seo Young Kim et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety
- (2011) Y. KOMANO et al. JOURNAL OF RHEUMATOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients
- (2010) A. Deodhar et al. ARTHRITIS CARE & RESEARCH
- Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
- (2009) R. K. Dore et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis associated with osteopetrosis
- (2009) Yuho Kadono et al. Modern Rheumatology
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
- (2008) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17
- (2008) M. Hashizume et al. RHEUMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started